CTLA4 and breast carcinoma: In summary, this work demonstrated the improved therapeutic efficacy achieving durable complete responses in the immunologically cold 4T1 murine breast cancer model of a novel combination immuno-oncology regimen comprising of the triple combination of N1, FSL-1, and R848 combined with CTLA4 ICB.